J&J reinforces Caplyta blockbuster projections, won’t shelve neuro prospectsnews2025-01-22T20:14:40+00:00January 22nd, 2025|Endpoints News|
J&J’s Spravato hit $1B in revenue in 2024news2025-01-22T12:30:38+00:00January 22nd, 2025|Endpoints News|
US withdrawal from WHO could jeopardize information sharingnews2025-01-21T21:35:52+00:00January 21st, 2025|Endpoints News|
Renewed mifepristone fight will test Trump’s abortion stancenews2025-01-21T21:32:32+00:00January 21st, 2025|Endpoints News|
J&J’s Spravato wins expanded label for depression as singular treatmentnews2025-01-21T17:58:40+00:00January 21st, 2025|Endpoints News|
Exiting Medicare director expects current law to guide next price negotiationsnews2025-01-21T12:00:49+00:00January 21st, 2025|Endpoints News|
Sage sues Biogen days after $469M buyout offernews2025-01-17T21:12:51+00:00January 17th, 2025|Endpoints News|
Novo claims high-dose Phase 3 Wegovy win but sales impact might be mutednews2025-01-17T15:23:48+00:00January 17th, 2025|Endpoints News|
Ozempic makes list for next Medicare negotiation roundnews2025-01-17T13:05:44+00:00January 17th, 2025|Endpoints News|
Amgen’s KRAS drug Lumakras clinches FDA green light in colorectal cancernews2025-01-17T11:22:19+00:00January 17th, 2025|Endpoints News|
